Microtubule associated protein tau (MAPT) irna formulations and methods of use thereof

TW202631159APending Publication Date: 2026-08-01ALNYLAM PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-10-16
Publication Date
2026-08-01

Smart Images

  • Figure TWG2TA001070891_001
    Figure TWG2TA001070891_001
  • Figure TWG2TA001070891_002
    Figure TWG2TA001070891_002
  • Figure TWG2TA001070891_003
    Figure TWG2TA001070891_003
Patent Text Reader

Abstract

The disclosure relates to formulations of double stranded ribonucleic acid (dsRNAi) agents targeting a MAPT gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated neurodegenerative disease or disorder, e.g., Alzheimer’s disease, FTD, PSP, or other tauopathy, using such dsRNAi agent formulations.
Need to check novelty before this filing date? Find Prior Art